Effect of Phenylbutazone Administration on Insulin Sensitivity in Horses With Insulin Dysregulation
Journal of Veterinary Internal Medicine · 2025
DOI: 10.1111/jvim.70028 ↗At a glance
Journal article in Journal of Veterinary Internal Medicine, 2025. Written by Kate L Kemp and 3 co-authors. Institution: School of Veterinary Science, The University of Queensland, Gatton, Queensland, Australia. Major MEDLINE topics: Phenylbutazone, Insulin Resistance, Horse Diseases, Insulin. Cited 1 times so far (Crossref); 47 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: The University of Queensland Graduate School Research Training Program Scholarship, The University of Queensland Destination Australia Scholarship, Morris Animal Foundation.
Abstract (original language)
Background
Phenylbutazone is prescribed to manage pain caused by hyperinsulinemia-associated laminitis. Phenylbutazone reduces glucose and insulin concentrations in horses with insulin dysregulation (ID) but the underlying mechanism of action is unknown. Hypothesis/Objectives Investigate the effect of phenylbutazone on tissue insulin sensitivity in horses. It is hypothesized that the reduced glucose and insulin concentrations in horses with ID receiving phenylbutazone are mediated by a higher tissue insulin sensitivity. Animals Fifteen light breed horses, including seven with ID.
Methods
Randomized cross-over study. Horses underwent a modified frequently sampled intravenous glucose tolerance test (mFSIGTT) after 8 days of treatment with phenylbutazone (4.4 mg/kg IV daily) or placebo (5 mL 0.9% saline IV daily). After a 10-day washout period, horses received the alternative treatment for 8 days and a second mFSIGTT. Minimal model analysis was performed, and the effects of ID status and phenylbutazone were investigated with p < 0.05 considered significant.
Results
In horses with ID, phenylbutazone increased tissue insulin sensitivity index (median [interquartile range]: 0.39 [0.14–0.74] vs. 0.56 [0.55–1.18] ×10−4 L/mIU/min, p = 0.03), and decreased glucose (21 726 [19 040–24 948] vs. 22 909 [22 496–26 166] mg/dL × min, p = 0.02) and insulin (19 595 [16 147—29 698] vs. 22 752 [20 578—31 826] μIU/mL × min, p = 0.03) areas under the curves. No effect was detected in horses administered placebo. Conclusion and Clinical Importance Phenylbutazone reduces insulin concentration in horses with ID by modulating tissue insulin sensitivity, suggesting that its relevance in the management of ID can extend beyond laminitis-associated pain.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- School of Veterinary Science, The University of Queensland, Gatton, Queensland, Australia.
- Elizabeth Macarthur Agricultural Institute, Department of Primary Industries, Menangle, New South Wales, Australia.
- School of Agriculture and Environmental Science, University of Southern Queensland, Queensland, Australia.
- College of Veterinary Medicine, Department of Veterinary Clinical Sciences, Purdue University, West Lafayette, Indiana, USA.
ORCID profiles: Kate L Kemp, Nicholas K Y Yuen, Jazmine E Skinner, François-René Bertin
Funding
- The University of Queensland Graduate School Research Training Program Scholarship
- The University of Queensland Destination Australia Scholarship
- Morris Animal Foundation
Cite
APA
Kemp, K. L., Yuen, N. K. Y., Skinner, J. E., & Bertin, F. R. (2025). Effect of Phenylbutazone Administration on Insulin Sensitivity in Horses With Insulin Dysregulation. Journal of Veterinary Internal Medicine. https://doi.org/10.1111/jvim.70028
Vancouver
Kemp KL, Yuen NKY, Skinner JE, Bertin FR. Effect of Phenylbutazone Administration on Insulin Sensitivity in Horses With Insulin Dysregulation. Journal of Veterinary Internal Medicine. 2025. doi:10.1111/jvim.70028
BibTeX
@article{Kemp2025,
author = {Kemp, Kate L and Yuen, Nicholas K Y and Skinner, Jazmine E and Bertin, François-René},
title = {Effect of Phenylbutazone Administration on Insulin Sensitivity in Horses With Insulin Dysregulation},
journal = {Journal of Veterinary Internal Medicine},
year = {2025},
doi = {10.1111/jvim.70028}
}
EUVIMED